Stock ELDN ELEDON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Eledon Pharmaceuticals, Inc.

Equities

ELDN

US28617K1016

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
2.99 USD -3.24% Intraday chart for Eledon Pharmaceuticals, Inc. +19.36% +66.11%
May. 07 Eledon Pharmaceuticals, Inc. Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection CI
May. 06 Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Eledon Pharmaceuticals, Inc. Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Eledon Pharmaceuticals Says 12th Participant Enrolled in Tegoprubart Trial; Shares Rise After Hours
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
Sector Update: Health Care
Eledon Pharmaceuticals Says Tegoprubart Used in Kidney Transplant From Pig to Human
USA-Un homme greffé avec le rein d'un porc, une première mondiale
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Eledon Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals, Inc. Appoints of Eliezer Katz as Chief Medical Officer
Eledon Pharmaceuticals Appoints Allan Douglas Kirk to Board of Directors
Eledon's Investigational Antibody Used in Treatment Regimen After Pig-to-Human Heart Transplant
Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023
Eledon Pharmaceuticals, Inc. Announces Publication of Study Evaluating Tegoprubart as an Immunomodulatory Monotherapy in Nonhuman Primate Kidney and Islet Allotransplants
Eledon Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 2 Bestow Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals, Inc. Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Eledon Pharmaceuticals, Inc. Announces Gary A. Lyons Not to Stand for Re-Election as Director
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELDN Stock
  4. News Eledon Pharmaceuticals, Inc.
  5. Other languages